Braidwell LP
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Braidwell LP reported 65 stock positions worth $2.3 billion. Its top holding was CG Oncology (CGON) at 5.2% of the portfolio, followed by Xenon Pharmaceuticals (XENE, 4.6%) and Neurocrine Biosciences (NBIX, 4.6%). Compared with Q2 2024, it opened 15 new positions, sold out of 8, added to 24 and reduced 22. The biggest buy was Apellis Pharmaceuticals (APLS, shares +411%) and the biggest sale an exit from Thermo Fisher Scientific (TMO).
- Most Recent 13F
- Q2 2026
- Location
- STAMFORD, CT
- CIK
- 0001920938
- Portfolio Value
- $2.3B (Q3 2024)
- SEC Filing
- 0001920938-24-000006 ↗ filed Nov 14, 2024
Holdings Value
Holdings 65 stocks · $2.3B
| CGON CG Oncology Inc. | 5.15% | 3,170,875 | $119.6M | Reduce -4.2% |
| XENE Xenon Pharmaceuticals Inc. | 4.59% | 2,707,255 | $106.6M | Add +5.7% |
| NBIX Neurocrine Biosciences Inc. | 4.55% | 917,674 | $105.7M | Add +20.9% |
| APGE Apogee Therapeutics Inc. | 4.16% | 1,643,226 | $96.5M | Reduce -31.3% |
| APLS Apellis Pharmaceuticals Inc. | 3.88% | 3,125,183 | $90.1M | Add +410.8% |
| ALGN Align Technology Inc. | 3.41% | 311,679 | $79.3M | Add +13.3% |
| GH Guardant Health Inc. | 3.30% | 3,342,124 | $76.7M | Add +19.0% |
| LEGN Legend Biotech Corp.-ADR | 3.23% | 1,541,551 | $75.1M | Reduce -7.7% |
| VKTX Viking Therapeutics Inc. | 3.15% | 1,156,977 | $73.2M | Add +4.5% |
| KNSA Kiniksa Pharmaceuticals Inte | 3.11% | 2,894,513 | $72.3M | Add +40.6% |
| PEN Penumbra Inc. | 3.02% | 361,428 | $70.2M | Add +70.0% |
| MRVI Maravai Lifesciences Hldgs-A | 2.99% | 8,353,287 | $69.4M | Reduce -7.4% |
| DAWN Day One Biopharmaceuticals I | 2.92% | 4,873,853 | $67.9M | Add +60.5% |
| SYRE Spyre Therapeutics Inc. | 2.77% | 2,189,836 | $64.4M | Reduce -12.9% |
| RGEN Repligen Corp. | 2.54% | 396,781 | $59.0M | Add +22.6% |
| IRTC Irhythm Holdings Inc. | 2.50% | 782,557 | $58.1M | Add +48.7% |
| ARGX Argenx SE - ADR | 2.26% | 96,724 | $52.4M | Reduce -42.1% |
| EWTX Edgewise Therapeutics Inc. | 2.25% | 1,958,310 | $52.3M | New |
| INSP Inspire Medical Systems Inc. | 2.17% | 238,911 | $50.4M | Reduce -37.0% |
| SRPT Sarepta Therapeutics Inc. | 1.99% | 370,400 | $46.3M | Add +352.3% |
| ISRG Intuitive Surgical Inc. | 1.93% | 91,300 | $44.9M | Reduce -9.2% |
| AVDL Avadel Pharmaceuticals Ltd. | 1.91% | 3,388,939 | $44.4M | Add +16.9% |
| BCAX Bicara Therapeutics Inc. | 1.82% | 1,657,600 | $42.2M | New |
| KROS Keros Therapeutics Inc. | 1.77% | 707,240 | $41.1M | Reduce -28.0% |
| GKOS Glaukos Corp. | 1.75% | 311,616 | $40.6M | Reduce -37.3% |
| MDGL Madrigal Pharmaceuticals Inc. | 1.68% | 183,818 | $39.0M | New |
| PCVX Vaxcyte Inc. | 1.46% | 297,568 | $34.0M | Reduce -63.2% |
| REPL Replimune Group Inc. | 1.45% | 3,070,837 | $33.7M | Add +203.0% |
| ARVN Arvinas Inc. | 1.36% | 1,284,472 | $31.6M | Add +148.3% |
| KRYS Krystal Biotech Inc. | 1.32% | 168,691 | $30.7M | Add +57.4% |
| KIDS Orthopediatrics Corp. | 1.29% | 1,107,770 | $30.0M | No change |
| DXCM Dexcom Inc. | 1.27% | 441,086 | $29.6M | New |
| BNTX Biontech SE-ADR | 1.27% | 247,750 | $29.4M | New |
| FNA Paragon 28 Inc. | 1.19% | 4,135,109 | $27.6M | Reduce -0.4% |
| RLAY Relay Therapeutics Inc. | 1.07% | 3,499,427 | $24.8M | Add +16.4% |
| ATEC Alphatec Holdings Inc. | 0.97% | 4,041,065 | $22.5M | Add +84.1% |
| HROW Harrow Inc. | 0.85% | 439,638 | $19.8M | Add +47.9% |
| CGEM Cullinan Therapeutics Inc. | 0.85% | 1,176,173 | $19.7M | Add +567.6% |
| EXAS Exact Sciences Corp. | 0.84% | 286,178 | $19.5M | Reduce -74.9% |
| OCUL Ocular Therapeutix Inc. | 0.84% | 2,239,770 | $19.5M | Add +36.3% |
| IMTX Immatics NV | 0.81% | 1,647,565 | $18.8M | New |
| IRWD Ironwood Pharmaceuticals Inc. | 0.79% | 4,438,232 | $18.3M | No change |
| BSX Boston Scientific Corp. | 0.68% | 189,200 | $15.9M | New |
| DNTH Dianthus Therapeutics Inc. | 0.58% | 493,687 | $13.5M | Add +34.6% |
| FDMT 4D Molecular Therapeutics Inc. | 0.57% | 1,225,448 | $13.2M | Add +231.7% |
| CELC Celcuity Inc. | 0.57% | 884,306 | $13.2M | Add +71.2% |
| ORKA Oruka Therapeutics Inc. | 0.54% | 515,726 | $12.6M | New |
| ALEC Alector Inc. | 0.43% | 2,158,245 | $10.1M | Reduce -9.3% |
| ZURA Zura Bio Ltd. | 0.43% | 2,472,806 | $10.0M | New |
| PODD Insulet Corp. | 0.43% | 42,500 | $9.9M | New |
| NVRO Nevro LLC filed as NEVRO CORP | 0.41% | 1,698,768 | $9.5M | No change |
| CSTL Castle Biosciences Inc. | 0.41% | 331,986 | $9.5M | Reduce -20.2% |
| XNCR Xencor Inc. | 0.40% | 466,448 | $9.4M | New |
| JSPR Jasper Therapeutics Inc. | 0.39% | 483,300 | $9.1M | New |
| BBIO Bridgebio Pharma Inc. | 0.33% | 298,400 | $7.6M | Reduce -13.7% |
| LXEO Lexeo Therapeutics Inc. | 0.28% | 728,777 | $6.6M | Reduce -47.3% |
| LUNG Pulmonx Corp. | 0.27% | 752,541 | $6.2M | No change |
| SKIN Skinhealth Systems Inc. filed as THE BEAUTY HEALTH COMPANY | 0.25% | 4,049,694 | $5.8M | Reduce -20.9% |
| FULC Fulcrum Therapeutics Inc. | 0.16% | 1,069,158 | $3.8M | New |
| VERV Verve Therapeutics Inc. | 0.13% | 623,980 | $3.0M | New |
| IOVA Iovance Biotherapeutics Inc. | 0.09% | 217,928 | $2.0M | Reduce -85.1% |
| HLVX Hillevax Inc. | 0.08% | 1,064,000 | $1.9M | New |
| LXRX Lexicon Pharmaceuticals Inc. | 0.05% | 801,584 | $1.3M | Reduce -90.3% |
| DBV TECHNOLOGIES S A | 0.05% | 1,630,542 | $1.1M | Reduce -33.2% |
| ELEV Elevation Oncology Inc. | 0.01% | 473,503 | $284K | Reduce -80.9% |
Other holdings (16): bonds, preferreds, convertibles and warrants · $1.2B (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| GUARDANT HEALTH INC (GH 0 11/15/27) | NOTE 11/1 · principal | 268,252,000 | $216.0M | No change |
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | 140,838,000 | $145.6M | No change |
| NOVOCURE LTD (NVCR 0 11/01/25) | NOTE 11/0 · principal | 140,834,000 | $133.3M | No change |
| NUVASIVE INC (GMED 0.375 03/15/25) | NOTE 0.375% 3/1 · principal | 114,206,000 | $111.9M | No change |
| NEOGENOMICS INC (NEO 0.25 01/15/28) | NOTE 0.250% 1/1 · principal | 116,381,000 | $96.9M | No change |
| IRONWOOD PHARMACEUTICALS (IRWD 1.5 06/15/26) | NOTE 1.500% 6/1 · principal | 92,740,000 | $82.5M | Add +3.3% |
| DEXCOM INC (DXCM 0.375 05/15/28) | NOTE 0.375% 5/1 · principal | 92,700,000 | $82.3M | Add +12.1% |
| INSULET CORPORATION (PODD 0.375 09/01/26) | NOTE 0.375% 9/0 · principal | 63,800,000 | $76.4M | Reduce -6.2% |
| DEXCOM INC (DXCM 0.25 11/15/25) | NOTE 0.250%11/1 · principal | 73,500,000 | $70.1M | No change |
| TRAVERE THERAPEUTICS INC (TVTX 2.5 09/15/25) | NOTE 2.500% 9/1 · principal | 56,031,000 | $53.5M | No change |
| ALPHATEC HOLDINGS INC (ATEC 0.75 08/01/26) | NOTE 0.750% 8/0 · principal | 58,217,000 | $52.5M | No change |
| BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29) | NOTE 2.250% 2/0 · principal | 53,594,000 | $45.0M | Reduce -18.3% |
| AMPHASTAR PHARMACEUTICAL (AMPH 2 03/15/29) | NOTE 2.000% 3/1 · principal | 18,400,000 | $19.5M | New |
| HAEMONETICS CORP (HAE 0 03/01/26) | NOTE 3/0 · principal | 11,500,000 | $10.6M | No change |
| CUTERA INC (CUTR 4 06/01/29) | NOTE 4.000% 6/0 · principal | 29,000,000 | $5.0M | No change |
| CUTERA INC (CUTR 2.25 06/01/28) | NOTE 2.250% 6/0 · principal | 25,240,000 | $4.0M | No change |
Total filed on the 13F, all lines: $3.5B.
Portfolio Sells Q2 2024 → Q3 2024
| TMO Thermo Fisher Scientific Inc. | Sold out | 0.00% | −1.99 |
| PCVX Vaxcyte Inc. | Reduce -63.2% | 1.46% | −1.66 |
| EXAS Exact Sciences Corp. | Reduce -74.9% | 0.84% | −1.63 |
| TMDX Transmedics Group Inc. | Sold out | 0.00% | −1.46 |
| ARGX Argenx SE - ADR | Reduce -42.1% | 2.26% | −1.42 |
| IMCR Immunocore Holdings PLC-ADR | Sold out | 0.00% | −1.38 |
| AKRO Akero Therapeutics Inc. | Sold out | 0.00% | −1.30 |
| GKOS Glaukos Corp. | Reduce -37.3% | 1.75% | −1.26 |
| LXEO Lexeo Therapeutics Inc. | Reduce -47.3% | 0.28% | −0.85 |
| APGE Apogee Therapeutics Inc. | Reduce -31.3% | 4.16% | −0.66 |
| LXRX Lexicon Pharmaceuticals Inc. | Reduce -90.3% | 0.05% | −0.66 |
| LEGN Legend Biotech Corp.-ADR | Reduce -7.7% | 3.23% | −0.55 |
| KROS Keros Therapeutics Inc. | Reduce -28.0% | 1.77% | −0.53 |
| IOVA Iovance Biotherapeutics Inc. | Reduce -85.1% | 0.09% | −0.51 |
| LIVN Livanova PLC | Sold out | 0.00% | −0.49 |
| INSP Inspire Medical Systems Inc. | Reduce -37.0% | 2.17% | −0.43 |
| ISRG Intuitive Surgical Inc. | Reduce -9.2% | 1.93% | −0.36 |
| ELEV Elevation Oncology Inc. | Reduce -80.9% | 0.01% | −0.33 |
| MRVI Maravai Lifesciences Hldgs-A | Reduce -7.4% | 2.99% | −0.32 |
| LBPH Longboard Pharmaceuticals Inc. | Sold out | 0.00% | −0.28 |
| FNA Paragon 28 Inc. | Reduce -0.4% | 1.19% | −0.26 |
| SYRE Spyre Therapeutics Inc. | Reduce -12.9% | 2.77% | −0.25 |
| SKIN Skinhealth Systems Inc. | Reduce -20.9% | 0.25% | −0.25 |
| CGON CG Oncology Inc. | Reduce -4.2% | 5.15% | −0.20 |
| OM Outset Medical Inc. | Sold out | 0.00% | −0.14 |
| BBIO Bridgebio Pharma Inc. | Reduce -13.7% | 0.33% | −0.12 |
| ALEC Alector Inc. | Reduce -9.3% | 0.43% | −0.12 |
| ETNB 89BIO Inc. | Sold out | 0.00% | −0.07 |
| CSTL Castle Biosciences Inc. | Reduce -20.2% | 0.41% | −0.06 |
| DBV TECHNOLOGIES S A | Reduce -33.2% | 0.05% | −0.05 |
Portfolio Buys Q2 2024 → Q3 2024
| APLS Apellis Pharmaceuticals Inc. | Add +410.8% | 3.88% | +2.68 |
| EWTX Edgewise Therapeutics Inc. | New | 2.25% | +2.25 |
| BCAX Bicara Therapeutics Inc. | New | 1.82% | +1.82 |
| MDGL Madrigal Pharmaceuticals Inc. | New | 1.68% | +1.68 |
| SRPT Sarepta Therapeutics Inc. | Add +352.3% | 1.99% | +1.33 |
| DXCM Dexcom Inc. | New | 1.27% | +1.27 |
| BNTX Biontech SE-ADR | New | 1.27% | +1.27 |
| KNSA Kiniksa Pharmaceuticals Inte | Add +40.6% | 3.11% | +1.15 |
| PEN Penumbra Inc. | Add +70.0% | 3.02% | +1.07 |
| REPL Replimune Group Inc. | Add +203.0% | 1.45% | +0.98 |
| IMTX Immatics NV | New | 0.81% | +0.81 |
| DAWN Day One Biopharmaceuticals I | Add +60.5% | 2.92% | +0.78 |
| CGEM Cullinan Therapeutics Inc. | Add +567.6% | 0.85% | +0.69 |
| BSX Boston Scientific Corp. | New | 0.68% | +0.68 |
| ARVN Arvinas Inc. | Add +148.3% | 1.36% | +0.66 |
| ORKA Oruka Therapeutics Inc. | New | 0.54% | +0.54 |
| HROW Harrow Inc. | Add +47.9% | 0.85% | +0.53 |
| RGEN Repligen Corp. | Add +22.6% | 2.54% | +0.45 |
| ZURA Zura Bio Ltd. | New | 0.43% | +0.43 |
| PODD Insulet Corp. | New | 0.43% | +0.43 |
| XNCR Xencor Inc. | New | 0.40% | +0.40 |
| JSPR Jasper Therapeutics Inc. | New | 0.39% | +0.39 |
| KRYS Krystal Biotech Inc. | Add +57.4% | 1.32% | +0.31 |
| OCUL Ocular Therapeutix Inc. | Add +36.3% | 0.84% | +0.26 |
| FDMT 4D Molecular Therapeutics Inc. | Add +231.7% | 0.57% | +0.17 |
| FULC Fulcrum Therapeutics Inc. | New | 0.16% | +0.16 |
| VKTX Viking Therapeutics Inc. | Add +4.5% | 3.15% | +0.15 |
| CELC Celcuity Inc. | Add +71.2% | 0.57% | +0.13 |
| VERV Verve Therapeutics Inc. | New | 0.13% | +0.13 |
| DNTH Dianthus Therapeutics Inc. | Add +34.6% | 0.58% | +0.10 |
| HLVX Hillevax Inc. | New | 0.08% | +0.08 |
| RLAY Relay Therapeutics Inc. | Add +16.4% | 1.07% | +0.06 |
| ALGN Align Technology Inc. | Add +13.3% | 3.41% | +0.01 |
| AVDL Avadel Pharmaceuticals Ltd. | Add +16.9% | 1.91% | −0.17 |
| ATEC Alphatec Holdings Inc. | Add +84.1% | 0.97% | −0.21 |
| IRTC Irhythm Holdings Inc. | Add +48.7% | 2.50% | −0.40 |
| XENE Xenon Pharmaceuticals Inc. | Add +5.7% | 4.59% | −0.52 |
| NBIX Neurocrine Biosciences Inc. | Add +20.9% | 4.55% | −0.80 |
| GH Guardant Health Inc. | Add +19.0% | 3.30% | −0.85 |
Notes & Other Activity Q2 2024 → Q3 2024
| IRONWOOD PHARMACEUTICALS (IRWD 1.5 06/15/26) | NOTE 1.500% 6/1 · principal | Add +3.3% | 92,740,000 | $82.5M |
| DEXCOM INC (DXCM 0.375 05/15/28) | NOTE 0.375% 5/1 · principal | Add +12.1% | 92,700,000 | $82.3M |
| INSULET CORPORATION (PODD 0.375 09/01/26) | NOTE 0.375% 9/0 · principal | Reduce -6.2% | 63,800,000 | $76.4M |
| SAREPTA THERAPEUTICS INC (SRPT 1.25 09/15/27) | NOTE 1.250% 9/1 · principal | Sold out | 43,066,000 | $55.5Mbefore exit |
| BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29) | NOTE 2.250% 2/0 · principal | Reduce -18.3% | 53,594,000 | $45.0M |
| AMPHASTAR PHARMACEUTICAL (AMPH 2 03/15/29) | NOTE 2.000% 3/1 · principal | New | 18,400,000 | $19.5M |
| CONMED CORP (CNMD 2.25 06/15/27) | NOTE 2.250% 6/1 · principal | Sold out | 5,000,000 | $4.5Mbefore exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 83 | $2.6B | CAI, HNGE, GKOS, EWTX, SYRE |
| Q1 2026 | 82 | $2.6B | CAI, NBIX, GKOS, CNTA, XENE |
| Q4 2025 | 68 | $2.6B | CAI, EWTX, NBIX, GKOS, NUVL |
| Q3 2025 | 64 | $2.5B | CAI, XENE, CGON, NBIX, KRYS |
| Q2 2025 | 45 | $2.1B | CAI, NBIX, XENE, ARGX, KRYS |
| Q1 2025 | 52 | $1.9B | NBIX, LEGN, ARGX, XENE, ALGN |
| Q4 2024 | 59 | $2.2B | NBIX, XENE, LEGN, CGON, GH |
| Q3 2024 | 65 | $2.3B | CGON, XENE, NBIX, APGE, APLS |
| Q2 2024 | 58 | $2.0B | NBIX, CGON, XENE, APGE, GH |
| Q1 2024 | 51 | $1.8B | APGE, NBIX, ARGX, PCVX, LEGN |